



下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEAlisporivirCat. No.: HY-12559CAS No.: 254435-95-5Synonyms: DEB-025; Debio-025; UNIL-025分式: CHNO分量: 1216.64作靶點(diǎn): HCV作通路: Anti-infection儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 100 mg/m
2、L (82.19 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 0.8219 mL 4.1097 mL 8.2194 mL5 mM 0.1644 mL 0.8219 mL 1.6439 mL10 mM 0.0822 mL 0.4110 mL 0.8219 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。體內(nèi)實(shí)驗(yàn) 請根據(jù)您的實(shí)驗(yàn)動物和給藥式選擇適當(dāng)?shù)娜芙獍福渲魄罢埾扰渲瞥蔚膬湟海僖来翁砑又軇?為保證實(shí)驗(yàn)結(jié)
3、果的可靠性,體內(nèi)實(shí)驗(yàn)的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄的儲備液可以根據(jù)儲存條件,適當(dāng)保存;以下溶劑前的百分指該溶劑在您配制終溶液中的體積占):1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (2.05 mM); Clear solution1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 Alisporivir (DEB-025; Debio-025)親環(huán)蛋抑制劑,具有效的抗丙型肝炎病毒 (HCV
4、) 活性的。體外研究 DEB025 binds to CypA, a peptidyl-prolyl cis-trans isomerase which is a crucial cofactor for HCV replication1. Alisporivir (Debio-025) is an analogue of cyclosporine A and represents the prototype of a new class ofnon-immunosuppressive cyclophilin inhibitors. Alisporivir prevents HCV prote
5、in-mediated collapse of therespiration-driven mitochondrial membrane potential. Alisporivir prevents HCV protein-mediatedmitochondrial dysfunction outside the context of apoptosis, calcium overload, production of ROS, dysfunction2. In cell culture models, low-micromolar doses of alisporivir block SA
6、RS-CoV and MERS-CoV replication.Combination treatment with alisporivir and ribavirin increases the anti-MERS-CoV activity in cell culture 3.Alisporivir pretreatment stimulates antigen presentation by hepatoma target cells, leading to enhancement ofantigen-specific CD8+ T cell activation by 40%. Alis
7、porivir induces an increase of MHC-I and beta-2microglobulin on the surface of several cell lines 4.體內(nèi)研究 Combination treatment with alisporivir and ribavirin does not protect against SARS-CoV infection in a mousemodel 3.PROTOCOLCell Assay 2 Alisporivir is prepared in DMSO at 4 mM and diluted in cell
8、 culture medium at the indicated concentrations(0.1, 0.2, 0.3, 0.4, 0.5 M). UHCV-32 and UHCVcon-57.3 are U-2 OS human osteosar coma-derived celllines inducibly expressing the entire open reading frame derived from the HCV H77 prototype and consensusclones, respectively. Cell viability is measured by
9、 trypan blue exclusion analysis. HCV protein expression inthese cells is induced by withdrawal of tetracycline from the culture medium. The effect of tetracycline on thenaive U2 OS cell line is tested measuring mitochondria-related respiration and reactive oxygen species(ROS) production, which remai
10、ns unchanged 2.MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Signal. 2019 May 4. pii: S0898-6568(19)30098-1.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Coelmont L, et al. DEB025 (Alisporivir) inhibits hepatitis C virus
11、replication by preventing a cyclophilin A induced cis-trans isomerisationin domain II of NS5A. PLoS One. 2010 Oct 27;5(10):e13687.2. Quarato G, et al. The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction. Hepatology. 2012May;55(5):1333-43.3. de Wilde AH
12、, et al. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in amouse model. Virus Res. 2017 Jan 15;228:7-13.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE4. Esser-Nobis K, et al. The cyclophilin-inhibitor alisporivir stimulates antigen presentation thereby promoting antigen-specific CD8(+) T cellactivation. J Hepatol. 2016 Jun;64(6):1305-14.McePdfHeightCaut
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 小學(xué)四年級上冊英語試卷單選題100道及答案
- 2025機(jī)械設(shè)備租賃合同樣本
- 2025合作合同書【合作經(jīng)營合同書】
- 上海中介租房服務(wù)合同書
- 投資合作合同書范例二零二五年
- 回購協(xié)議合同書二零二五年
- 2025年上海長期服務(wù)合同
- 2025年餐飲企業(yè)供應(yīng)合同樣本
- 2025修訂后造價師聘用合同
- 2025物業(yè)管理服務(wù)合同(派遣制范本)
- 小學(xué)三年級音樂《馬蘭謠》課件
- “當(dāng)代文化參與”學(xué)習(xí)任務(wù)群相關(guān)單元的設(shè)計(jì)思路與教學(xué)建議課件(共51張PPT)
- 提高臥床患者踝泵運(yùn)動的執(zhí)行率品管圈匯報書模板課件
- 同理心的應(yīng)用教學(xué)教材課件
- DB4102-T 025-2021海綿城市建設(shè)施工與質(zhì)量驗(yàn)收規(guī)范-(高清現(xiàn)行)
- 城市軌道交通安全管理隱患清單
- 錫膏使用記錄表
- 兒童保健學(xué)課件:緒論
- 中小學(xué)校園安全穩(wěn)定工作崗位責(zé)任清單
- 校園安全存在問題及對策
- NY∕T 309-1996 全國耕地類型區(qū)、耕地地力等級劃分
評論
0/150
提交評論